Intellia Broadens Its Oncology Bets With CRISPR-Edited NK Cell Therapies
Partners ONK Therapeutics To Develop Five Candidates
Intellia continues to expand across immuno-oncology, adding the promise of natural killer cells to its pipeline.
You may also be interested in...
After ending 2022 with more than $1bn in cash, the US firm is keen to validate its in vivo approach to gene therapy with investigational new drug applications and pivotal trials lined up for two core rare disease programs.
AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.
The first use of CRISPR/Cas9 in humans shows promising safety and efficacy against rare disease ATTR, and opens up the possibility of treating many genetic diseases.